Research Project
Grant-in-Aid for Young Scientists (B)
The aim for this study is to development of an efficient and convenient cancer immunotherapy and to elucidate the mechanism when combining the selective COX-2 inhibitor celecoxib and the type I IFN inducer 2’3’-cGAMP.We used different mouse tumor models to determine the treatment regimen of celecoxib and 2’3’-cGAMP. The combination therapy showed a significant antitumor effect on tumor growth in mice compared to control and monotherapy with celecoxib or 2’3’-cGAMP. The antitumor effect of the combination therapy was not dependent on CD8+ T-cells and macrophages, and it was suggested that the type I IFN signaling pathway may not be involved in the antitumor responses of the combination therapy.
All 2017
All Journal Article (1 results) (of which Int'l Joint Research: 1 results, Peer Reviewed: 1 results, Open Access: 1 results, Acknowledgement Compliant: 1 results)
Cancer Immunology, Immunotherapy
Volume: - Issue: 6 Pages: 705-716
10.1007/s00262-017-1975-1